Lyra Therapeutics, Inc. LYRA
Set alert
0.19 USD 0.00 0.00%
At close · Oct 29
0.35 +0.16 +84.47%
After hours · Oct 29, 4:00 PM ET
0.3623 Day range 0.52
0.0004 52-week range 5.82
- YTD
- -93.83%
- 1 year
- -96.74%
- Open
- 0.4501
- Prev close
- 0.19
- Mkt cap
- 337.23K
- Vol
- 5.47K
- Avg vol
- 907
- EPS
- -18.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3623
- High
- 0.52
- Forward P/E
- -0.24
- Beta
- -0.04
- Short ratio
- 0.89
- Inst. own
- 59.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.2216
- 200-d avg
- 1.32
- 1y target
- 1.25
2Y chart
Events in this range
- Nov 12, 2024Earnings: -0.18; estimate -0.23; surprise 21.74%
- May 28, 2025Split: 1 for 50
Signals (70)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 28, 2026 | 2 months ago |
| RSI: Oversold | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| RSI: Oversold | Apr 8, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| RSI: Oversold | Mar 16, 2026 | 7 months ago |
| RSI: Oversold | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| RSI: Oversold | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 30, 2026 | 9 months ago |
| RSI: Oversold | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| RSI: Oversold | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| RSI: Oversold | Nov 6, 2025 | 11 months ago |
| RSI: Oversold | Oct 30, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 2, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 19, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 3, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| RSI: Overbought | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| RSI: Oversold | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| SMA: Bullish | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 20, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 19, 2024 | 1 year ago |
Key statistics
- Market cap
- 11.45M
- Enterprise value
- -4.52M
- Trailing P/E
- 0.00
- Forward P/E
- -0.24
- PEG ratio
- 0.00
- Price / sales
- 7.78
- Price / book
- 0.56
- EPS (TTM)
- -1.49
- Beta
- -0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.47M
- Revenue growth
- -64.20%
- Free cash flow
- -45.86M
- Total cash
- 51.63M
- Total debt
- 35.32M
- Return on equity
- -186.18%
- Shares outstanding
- 65.46M
- Short % of float
- 4.20%
- 50-day average
- 0.2216
- 200-day average
- 1.32
Analyst view
Consensus: none
Price target (mean) 1.25 +557.9% upside
Now 0.19
- Target (low)
- 0.50
- Target (mean)
- 1.25
- Target (high)
- 2.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.13.
Financials — quick view
LYRA Revenue — quarterly 25.00K
LYRA Net income — quarterly -5.98M
LYRA EPS — quarterly -3.38
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.23 | -0.18 | +0.05 | +21.74% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | -0.29 | +0.05 | +14.71% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.26 | -0.35 | -0.09 | -34.62% |
| Mar 21, 2024 | Dec 1, 2023 | -0.33 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| May 7, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| May 7, 2024 | Jefferies | down | Buy | Hold |
| May 6, 2024 | BTIG | down | Buy | Neutral |
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyratherapeutics.com
News
- Lyra Therapeutics (OTCMKTS:LYRA) versus Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Analysis
- ARS Pharmaceuticals (NASDAQ:SPRY) vs. Lyra Therapeutics (OTCMKTS:LYRA) Head to Head Review
- Head to Head Contrast: Lyra Therapeutics (OTCMKTS:LYRA) versus Cronos Group (NASDAQ:CRON)
- Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Gold Rises Sharply; Lyra Therapeutics Shares Plunge
- 12 Health Care Stocks Moving In Monday's Intraday Session
- US Stocks Lower; Dow Tumbles Over 250 Points
Your note
Sign in to keep a note on LYRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON EDWARD T | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 30, 2023 | 0 |
| CAVALIER JASON | Chief Financial Officer | Stock Award(Grant) | Oct 15, 2024 | 100,000 |
| NBVM GP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 30, 2023 | 0 |
| NOYES CORINNE | Officer | Stock Award(Grant) | Jan 30, 2023 | 36,667 |
| PALASIS MARIA | Chief Executive Officer | Stock Award(Grant) | Oct 15, 2024 | 300,000 |
| PERCEPTIVE ADVISORS LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 30, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 19.49% | 12,757,562 | 2.23M | Sep 29, 2024 |
| Citadel Advisors Llc | 7.29% | 4,772,816 | 834.76K | Sep 29, 2024 |
| Blackrock Inc. | 4.57% | 2,993,626 | 523.59K | Sep 29, 2024 |
| Samsara BioCapital, LLC | 4.25% | 2,780,261 | 486.27K | Sep 29, 2024 |
| Vanguard Group Inc | 2.72% | 1,779,263 | 311.19K | Sep 29, 2024 |
| Ikarian Capital, LLC | 1.61% | 1,056,829 | 184.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 3.55% | 2,323,232 | 406.33K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.52% | 992,543 | 173.59K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.70% | 455,832 | 79.72K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.63% | 409,835 | 71.68K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.49% | 323,038 | 56.50K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 232,767 | 40.71K | Oct 30, 2024 |